{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:00:14Z","timestamp":1788836414888,"version":"build-2803163510"},"reference-count":27,"publisher":"Portland Press Ltd.","issue":"3","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Diabetes mellitus is a chronic metabolic disease that occurs when the pancreas is not producing enough insulin or when the insulin that it does produce is not able to be used effectively in the body. This results in hyperglycemia and if the blood sugars are not controlled, then it can lead to serious damage of various body systems, especially the nerves and the blood vessels. Uncontrolled diabetes is a major cause of kidney failure, heart attacks, stroke and amputation. One of the most devastating complications for patients is diabetic retinopathy (DR) which represents the leading cause of preventable vision loss in people between 20 and 65 years of age. Sodium glucose transporter 2 (SGLT2) inhibitors have been shown to reduce the risk for cardiovascular and renal events, however literature highlighting their potential role to prevent DR is limited. We therefore used a relevant mouse model (Akimba) to explore the effects of the SGLT2 inhibitor, Empagliflozin (EMPA), on the development of diabetic retinal changes. Here we show that when given in the early stages of type 1 diabetes (T1D), EMPA reduced the weight loss usually associated with T1D, decreased diabetes-associated polydipsia, lowered fasting blood glucose levels, decreased kidney-to-body weight ratios and, most importantly in the current context, substantially reduced retinal abnormalities associated with DR. We show that EMPA reduces vascular leakage indicated by lower albumin staining in the vitreous humor and diminishes expression of the pathogenic factor VEGF in the retina. Additionally, EMPA significantly alters the retinal genetic signature. Our findings suggest that SGLT2 inhibition may be a useful therapeutic approach to prevent the development of DR and its severity if given early in the disease process.<\/jats:p>","DOI":"10.1042\/bsr20212209","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T10:15:09Z","timestamp":1646216109000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy"],"prefix":"10.1042","volume":"42","author":[{"given":"Jennifer","family":"Matthews","sequence":"first","affiliation":[{"name":"Dobney Hypertension Centre, School of Biomedical Sciences \u2013 Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshini","family":"Herat","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, School of Biomedical Sciences \u2013 Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rooney","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, School of Biomedical Sciences \u2013 Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rakoczy","sequence":"additional","affiliation":[{"name":"Department of Molecular Ophthalmology, University of Western Australia, Crawley, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schlaich","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, School of Medicine \u2013 Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia"},{"name":"Department of Cardiology and Department of Nephrology, Royal Perth Hospital, Perth WA 6000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9804-9344","authenticated-orcid":false,"given":"Vance B.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, School of Biomedical Sciences \u2013 Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"2022030210143579900_B1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2022030210143579900_B2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4103\/0301-4738.100542","article-title":"The worldwide epidemic of diabetic retinopathy","volume":"60","author":"Zheng","year":"2012","journal-title":"Indian J. Ophthalmol."},{"key":"2022030210143579900_B3","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2214-109X(13)70113-X","article-title":"Causes of vision loss worldwide, 1990-2010: a systematic analysis","author":"Bourne","year":"2013","journal-title":"Lancet Glob. Health"},{"key":"2022030210143579900_B4","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.2353\/ajpath.2010.090883","article-title":"Characterization of a mouse model of hyperglycemia and retinal neovascularization","volume":"177","author":"Rakoczy","year":"2010","journal-title":"Am. J. Pathol."},{"key":"2022030210143579900_B5","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Opththalmology"},{"key":"2022030210143579900_B6","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/ijms19061816","article-title":"Diabetic retinopathy: pathophysiology and treatments","volume":"19","author":"Wang","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"2022030210143579900_B7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthamol."},{"key":"2022030210143579900_B8","doi-asserted-by":"publisher","first-page":"2042018819891886","DOI":"10.1177\/2042018819891886","article-title":"How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology","volume":"10","author":"May","year":"2019","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"2022030210143579900_B9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/bjo.79.4.362","article-title":"Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients","volume":"79","author":"Stitt","year":"1995","journal-title":"Br. J. Ophthalmol."},{"key":"2022030210143579900_B10","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J. Hypertens."},{"key":"2022030210143579900_B11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2353\/ajpath.2009.090264","article-title":"Surgical denervation of ocular sympathetic afferents decreases local transforming growth factor-beta and abolishes immune privilege","volume":"175","author":"Vega","year":"2009","journal-title":"Am. J. Pathol."},{"key":"2022030210143579900_B12","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1038\/s41598-018-21198-z","article-title":"The NLRP3 inflammasome may contribute to pathologic neovascularization in the advanced stages of diabetic retinopathy","volume":"8","author":"Chaurasia","year":"2018","journal-title":"Sci. Rep."},{"key":"2022030210143579900_B13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.exer.2014.03.005","article-title":"Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy","volume":"122","author":"Wisniewska-Kruk","year":"2014","journal-title":"Exp. Eye Res."},{"key":"2022030210143579900_B14","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s00125-006-0274-8","article-title":"Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model","volume":"49","author":"Shen","year":"2006","journal-title":"Diabetologia"},{"key":"2022030210143579900_B15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/bjo.2004.059089","article-title":"Generation of transgenic mice with mild and severe retinal neovascularisation","volume":"89","author":"Lai","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"2022030210143579900_B16","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1167\/iovs.11-8601","article-title":"Changes in murine hyalocytes are valuable early indicators of ocular disease","volume":"53","author":"Vagaja","year":"2012","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2022030210143579900_B17","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1167\/iovs.04-1340","article-title":"The Ins2Akita mouse as a model of early retinal complications in diabetes","volume":"46","author":"Barber","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2022030210143579900_B18","doi-asserted-by":"publisher","first-page":"R322","DOI":"10.1152\/ajpregu.00030.2004","article-title":"Cytokine gene expression in human skeletal muscle during concentric contraction: evidence that IL-8, like IL-6, is influenced by glycogen availability","volume":"287","author":"Chan","year":"2004","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2022030210143579900_B19","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1167\/iovs.14-16289","article-title":"Characterization of retinal vascular and neural damage in a novel model of diabetic retinopathy","volume":"56","author":"Weerasekera","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2022030210143579900_B20","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2022030210143579900_B21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.lfs.2016.01.042","article-title":"Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats","volume":"147","author":"Takakura","year":"2016","journal-title":"Life Sci."},{"key":"2022030210143579900_B22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev.ph.57.030195.001403","article-title":"Progression of renal disease and renal hypertrophy","volume":"57","author":"Hostetter","year":"1995","journal-title":"Annu. Rev. Physiol."},{"key":"2022030210143579900_B23","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","article-title":"A Central role for inflammation in the pathogenesis of diabetic retinopathy","volume":"18","author":"Joussen","year":"2004","journal-title":"FASEB J."},{"key":"2022030210143579900_B24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2337\/dc13-2002","article-title":"Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy","volume":"37","author":"Simo","year":"2014","journal-title":"Diabetes Care"},{"key":"2022030210143579900_B25","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1136\/bjo.2007.117309","article-title":"Effect of anti-VEGF antibody on retinal ganglion cells in rat","volume":"91","author":"Iriyama","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"2022030210143579900_B26","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.2337\/db06-1694","article-title":"Proteolytic degradation of VE-Cadherin alters the blood-retinal barrier in diabetes","volume":"56","author":"Navaratna","year":"2007","journal-title":"Diabetes"},{"key":"2022030210143579900_B27","doi-asserted-by":"publisher","first-page":"1.7.1","DOI":"10.1002\/cpbi.18","article-title":"Searching the Mouse Genome Informatics (MGI) resources for information on mouse biology from genotype to phenotype","volume":"56","author":"Shaw","year":"2016","journal-title":"Curr. Protoc. Bioinformatics"}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20212209\/930547\/bsr-2021-2209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20212209\/930547\/bsr-2021-2209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T10:15:11Z","timestamp":1646216111000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/42\/3\/BSR20212209\/230970\/Determining-the-role-of-SGLT2-inhibition-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20212209","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3]]},"published":{"date-parts":[[2022,3]]},"article-number":"BSR20212209"}}